Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Health Catalyst (HCAT) Research & Development (2018 - 2026)

Health Catalyst filings provide 9 years of Research & Development readings, the most recent being $9.8 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 35.61% to $9.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $44.4 million, a 23.86% decrease, with the full-year FY2025 number at $49.8 million, down 14.12% from a year prior.
  • Research & Development hit $9.8 million in Q1 2026 for Health Catalyst, down from $9.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $20.8 million in Q3 2022 to a low of $9.8 million in Q1 2026.
  • Median Research & Development over the past 5 years was $15.2 million (2025), compared with a mean of $15.6 million.
  • Biggest five-year swings in Research & Development: grew 26.76% in 2022 and later plummeted 35.61% in 2026.
  • Health Catalyst's Research & Development stood at $19.6 million in 2022, then rose by 3.44% to $20.3 million in 2023, then decreased by 26.05% to $15.0 million in 2024, then plummeted by 33.94% to $9.9 million in 2025, then decreased by 1.33% to $9.8 million in 2026.
  • The last three reported values for Research & Development were $9.8 million (Q1 2026), $9.9 million (Q4 2025), and $12.3 million (Q3 2025) per Business Quant data.